Organon & Co.(OGN)Stock Analysis

OGN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Organon & Co. (OGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OGN at 55.1/100 on a 32-signal composite quality model, placing it at rank #1,176 of 2,879 stocks — the top half of the AI-ranked universe. OGN scores in the top quartile across revenue scale (81.3). Areas of concern include earnings quality (25.8) and revenue growth (29.3), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), Organon & Co. reports quarterly revenue of $1.5B, net income of $146.0M, free cash flow of $188.0M. Top institutional holders of OGN by reported 13-F value include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. OGN trades on the NYSE exchange and files with the SEC under CIK 1821825. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Organon & Co. directly from SEC EDGAR.